These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

680 related articles for article (PubMed ID: 11776289)

  • 21. Medical devices; medical device, user facility, distributor, and manufacturer reporting, certification, and registration--FDA. Tentative final rule.
    Fed Regist; 1991 Nov; 56(228):60024-39. PubMed ID: 10115705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Applications for Food and Drug Administration application approval to market a new drug; revision of postmarketing reporting requirements. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Oct; 72(201):58993-9000. PubMed ID: 17966558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tobacco products, exemptions from substantial equivalence requirements. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2011 Jul; 76(128):38961-75. PubMed ID: 21735763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conforming regulations regarding removal of section 507 of the Federal Food, Drug, and Cosmetic Act; confirmation of effective date. Food and Drug Administration, HHS. Direct final rule; confirmation of effective date.
    Fed Regist; 1999 May; 64(94):26657. PubMed ID: 10558515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Sep; 73(189):56487-91. PubMed ID: 18985960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medical devices; establishment registration and device listing for manufacturers and distributors of devices; correction--FDA. Proposed rule; correction.
    Fed Regist; 1998 Nov; 63(228):65566. PubMed ID: 10338876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Aug; 73(164):49603-10. PubMed ID: 18958946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. When can a veterinarian import a foreign drug?
    Curry-Galvin E
    J Am Vet Med Assoc; 2005 Aug; 227(4):538-9. PubMed ID: 16117056
    [No Abstract]   [Full Text] [Related]  

  • 29. Biological products: reporting of biological product deviations in manufacturing. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Nov; 65(216):66621-35. PubMed ID: 11503696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigational new drug applications; clinical holds; companion document to direct final rule--FDA. Proposed rule.
    Fed Regist; 1998 Dec; 63(239):68710-2. PubMed ID: 10187560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Delegations of authority and organization; Office of the Commissioner--FDA. Final rule.
    Fed Regist; 1991 Nov; 56(225):58758. PubMed ID: 10115698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Requirements on content and format of labeling for human prescription drug and biological products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2006 Jan; 71(15):3921-97. PubMed ID: 16479698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current good tissue practice for human cell, tissue, and cellular and tissue-based product establishments; inspection and enforcement. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Nov; 69(226):68611-88. PubMed ID: 15562555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; policies, requirements, and administrative procedures; delay of effective date; reopening of administrative record. Food and Drug Administration, HHS. Final rule; delay of effective date; reopening of administrative record.
    Fed Regist; 2000 May; 65(86):25639-41. PubMed ID: 11010689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biological products regulated under Section 351 of the Public Health Services Act; implementation of biologics license; elimination of establishment license and product license--FDA. Proposed rule.
    Fed Regist; 1998 Jul; 63(147):40858-71. PubMed ID: 10181717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biologics products; establishment registration and product listing for manufacturers of human blood and blood products; amendment to exempt certain transfusion services from registration--FDA. Final rule.
    Fed Regist; 1984 Aug; 49(171):34448-51. PubMed ID: 10299643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amendment to the current good manufacturing practice regulations for finished pharmaceuticals. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Dec; 72(232):68064-70. PubMed ID: 18064770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human cells, tissues, and cellular and tissue-based products; establishment registration and listing. Interim final rule; opportunity for public comment.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Jan; 69(17):3823-6. PubMed ID: 14968801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmaceuticals and medical devices: FDA oversight.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2009 Jan; ():1-28. PubMed ID: 19297718
    [No Abstract]   [Full Text] [Related]  

  • 40. Medical devices; medical device reporting. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Feb; 70(38):9516-28. PubMed ID: 15736310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.